Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 628-633

  Traina, Tiffany A ^a   Rugo, Hope S ^a   Caravelli, James F ^a   Patil, Sujata ^a   Yeh, Benjamin ^a   Melisko, Michele E ^a   Park, John W ^a   Geneus, Stephanie ^a   Paulson, Matthew ^a   Grothusen, Jill ^a   Seidman, Andrew D ^a   Fornier, Monica ^a   Lake, Diana ^a   Dang, Chau ^a   Robson, Mark ^a   Theodoulou, Maria ^a   Flombaum, Carlos D ^a   Norton, Larry ^a   Hudis, Clifford A ^a   Dickler, Maura N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LETROZOLE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NITRILE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BONE NECROSIS; BREAST CANCER; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; HYPONATREMIA; METASTASIS; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; TREATMENT RESPONSE; VOMITING; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; LUNG TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SOFT TISSUE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NITRILES; PROGNOSIS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 77449129151     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8784     Document Type: Article

References (39)

1. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004 (Pubitemid 38298988)
2. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002 (Pubitemid 34694019)
3. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
4. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
5. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
6. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003
7. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and a 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
8. Brewster AM, Hortobagyi GN, Broglio KR, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100:1179-1183, 2008
9. Massarweh S, Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities. Clin Cancer Res 13:1950-1954, 2007
10. Osborne CK, Shou J, Massarweh S, et al: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-870s, 2005
11. Losordo DW, Isner JM: Estrogen and angiogenesis: A review. Arterioscler Thromb Vasc Biol 21:6-12, 2001
12. Morales DE, McGowan KA, Grant DS, et al: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91:755-763, 1995
13. Gagliardi AR, Hennig B, Collins DC: Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 16:1101-1106, 1996 (Pubitemid 26229771)
14. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
15. Kazi AA, Jones JM, Koos RD: Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: Estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol Endocrinol 19:2006-2019, 2005
16. Takei H, Lee ES, Jordan VC: In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9:39-42, 2002
17. Nakamura J, Savinov A, Lu Q, et al: Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a) anthracene-induced rat mammary tumors. Endocrinology 137: 5589-5596, 1996 (Pubitemid 26423128)
18. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95:10820-10825, 1998 (Pubitemid 28413152)
19. Manders P, Beex LV, Tjan-Heijnen VC, et al: Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98:2125-2132, 2003 (Pubitemid 37392415)
20. Linderholm B, Grankvist K, Wilking N, et al: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18:1423-1431, 2000 (Pubitemid 30205387)
21. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003
22. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989 (Pubitemid 19099520)
25. Roodhart JM, Langenberg MH, Witteveen E, et al: The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143, 2008
26. Zhu X, Wu S, Dahut WL, et al: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49:186-193, 2007 (Pubitemid 46178407)
27. Forero-Torres A, Galleshaw J, Jones C, et al: A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J Clin Oncol 26:37s, 2008 (suppl; abstr 625)
28. Falkson C, Rossman JF, Nabell L, et al: A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients. J Clin Oncol 26:59s, 2008 (suppl; abstr 1074)
29. Mouridsen H, Keshaviah A, Coates AS, et al: Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722, 2007
30. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001 (Pubitemid 32642188)
31. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008
32. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
33. Dimmeler S, Fleming I, Fisslthaler B, et al: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605, 1999 (Pubitemid 29279182)
34. Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129-1136, 2008
35. Tsatsaris V, Goffin F, Munaut C, et al: Over-expression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 88:5555-5563, 2003 (Pubitemid 37452769)
36. Estilo CL, Van Poznak CH, Wiliams T, et al: Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13:911-920, 2008
37. Estilo CL, Fornier M, Farooki A, et al: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26:4037-4038, 2008
38. McArthur HL, Estilo C, Huryn J, et al: Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol 26:523s, 2008 (suppl; abstr 9588)
39. Subramaniam DS, Wilkinson M, Liu M, et al: Sorafenib in hormone-receptor positive metastatic breast cancer resistant to aromatase inhibitors. Presented at the 2008 Breast Cancer Symposium, Washington, DC, September 5-7, 2008